Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IGHID 12616 - Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy (RELAI) - The RELAI Study

NCT07895823 is registered in ClinicalTrials.gov with University of North Carolina, Chapel Hill as lead sponsor.

NCT NCT07895823 Not yet recruiting Phase 4 40 participants (estimated) Started 2027 1 site

Follow this trial by email Email me the PDF

Get the NCT07895823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started January 2027. Interventional study, Phase 4, 40 participants (estimated). Lead sponsor University of North Carolina, Chapel Hill; United States. Primary measures: Percent of preliminarily eligible participants who accept and receive field-based injection (acceptability); Median acceptability of intervention (AIM) score (acceptability) and 2 more.

How it compares

413 similar trials: same condition (HIV Infections) and phase

Enrollment

This trial
40
Middle half
30 to 200
Median
70
Trials with a value
408

Months from start to completion

This trial
20
Middle half
21.1 to 45.9
Median
30.7
Trials with a value
376

Sites

This trial
1
Middle half
1 to 6
Median
1
Trials with a value
397
Posted results or a linked paper 56% 231 of 413 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
IGHID 12616 - Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy (RELAI) - The RELAI Study
Lead sponsor
University of North Carolina, Chapel Hill
Phase
Phase 4
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
September 30, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

HIV Infections

Registry terms: hiv infection

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
United States
Lead sponsor
University of North Carolina, Chapel Hill

Arms

As registered; 1 arm.

Registered arms
Arm Type Interventions
Field-based LA-CAB/RPV Experimental Field-based LA-CAB/RPV

Primary endpoints

Registered primary outcome measures; 4 primary.

Registered primary endpoints
Measure Time frame
Percent of preliminarily eligible participants who accept and receive field-based injection (acceptability) From enrollment to the end of participation at 7 months
Median acceptability of intervention (AIM) score (acceptability) Month 3, Month 7
Show registry wording

AIM scores are calculated using the following scale: 1 = Completely disagree, 2 = Disagree, 3 = Neither agree nor disagree, 4 = Agree, 5 = Completely agree. Scores are calculated from a version of the following four questions: (1) The intervention meets my approval, (2) The intervention is appealing to me, (3) I like the intervention, and (4) I welcome the intervention. Scores are summed across participant and summaries of these scores are provided, minimum score is 4 and maximum score is 20 which corresponds to perfect acceptability.

Median HIV treatment burden score (acceptability) Month 0, Month 3, Month 7
Show registry wording

The Treatment burden Questionnaire (TBQ) is a self-reported questionnaire assessing the burden of treatment without restricting its scope to a single condition or treatment context. It has been adapted to include 13 items rated on a Likert scale ranging from 0 (not at all difficult) to 5 (extremely difficult) related to the burden associated with taking medicine, self-monitoring, laboratory tests, physician visits, need for organization, administrative tasks, following advice on diet and physical activity, and social impact of the treatment. Item scores can be summed into a global score, ranging from 13 to 65. Higher scores reflect higher treatment burden.

Percentage of participants who receive all indicated LA-CAB/RPV injections within the allowable 14-day window (feasibility) From enrollment to the end of participation at 7 months
Show registry wording

As extracted from study administration and, where appropriate, clinic records, the date of injections will be determined as falling within or outside the acceptable window period. This outcome will be calculated as the percent of all participants with an indication for receipt of LA-CAB/RPV (that is, has not been excluded from further injections identified after receipt of first injection or failure to achieve appropriate decline in HIV RNA levels or viral suppression prompting transition to alternative agent), who receive all indicated injections within the acceptable 14-day window period, as determined by the date of the prior injection.

Lead sponsor's other trials

University of North Carolina, Chapel Hill, most recent start first.

Similar trials

Same condition (HIV Infections) and phase, most recent start first.